Positive early data supports Telix's pipeline differentiation; monitor full efficacy results from OPTIMAL-PSMA and regulatory milestones for TLX597-Tx and TLX591-Tx (Phase 3 ProstACT Global).
Price Chart
Executive Summary
Telix announces positive dosimetry data from Phase 2 OPTIMAL-PSMA trial of TLX597-Tx in mCRPC, showing low salivary gland and kidney uptake enabling dose intensification. The company is initiating a Phase 2 study (OPTIMAL-E) in mHSPC, advancing its pipeline in earlier-stage prostate cancer.
Key Facts
- TLX597-Tx dosimetry demonstrates reduced radiation to salivary glands and kidneys compared to existing PSMA RLTs.
- Dose-intensification regimen (8.5 GBq per cycle) shows potential for higher tumor uptake and wider therapeutic window.
- Phase 2 OPTIMAL-E trial initiated in metastatic hormone-sensitive prostate cancer (mHSPC).
- Data presented at 2026 International Prostate Cancer Symposium (IPCS 2026).
Financial Impact
No financial figures disclosed; potential depends on future clinical success and regulatory approval.
Risk Factors
- Clinical trial failure or safety issues in later stages.
- Competition from other PSMA-targeted therapies (e.g., Pluvicto).
- Regulatory approval uncertainty and commercialization challenges.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3284336 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $12.83 $11.95 | ▼ −6.86% | ▼ −8.99% | $10.55 (−17.77%) |
Sep 14, 2026 18d ago | Press Release | $11.78 $11.31 | ▼ −3.99% | ▼ −4.10% | $10.55 (−10.44%) |
Sep 2, 2026 4w ago | 6-K | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Sep 1, 2026 4w ago | Press Release | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Aug 20, 2026 6w ago | 6-K | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Aug 20, 2026 6w ago | Press Release | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Jul 30, 2026 9w ago | Press Release | $9.89 $11.52 | ▲ +16.48% | ▲ +12.97% | $10.55 (+6.67%) |
Jul 21, 2026 10w ago | Press Release | $10.32 $10.10 | ▼ −2.13% | ▲ +0.27% | $10.55 (+2.23%) |
Jul 21, 2026 10w ago | 6-K | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
Jul 20, 2026 10w ago | Press Release | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access